Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ARAVIVE, INC stock logo
ARAV
ARAVIVE
$0.04
$0.04
$0.04
$2.46
$2.95MN/AN/AN/A
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$22.09
+0.8%
$20.34
$13.45
$44.42
$1.93B0.031.03 million shs522,894 shs
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
$35.87
+2.0%
$35.99
$1.72
$54.30
$219.52M1.01362,174 shs24,007 shs
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
$9.36
$9.36
$9.10
$12.00
$167.08M0.53600 shsN/A
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
$0.00
$0.07
$4.08
$3.50M2.57848,888 shs9.65 million shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ARAVIVE, INC stock logo
ARAV
ARAVIVE
0.00%0.00%0.00%0.00%0.00%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
0.00%+3.37%+1.66%+45.90%-35.52%
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
0.00%+6.76%-3.34%+24.16%+896.25%
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
0.00%0.00%0.00%0.00%-22.00%
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
0.00%0.00%0.00%0.00%+6,910.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ARAVIVE, INC stock logo
ARAV
ARAVIVE
N/AN/AN/AN/AN/AN/AN/AN/A
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
2.3889 of 5 stars
3.51.00.04.40.01.70.0
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
3.0466 of 5 stars
3.45.00.00.02.81.70.0
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ARAVIVE, INC stock logo
ARAV
ARAVIVE
0.00
N/AN/AN/A
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
2.93
Moderate Buy$53.42141.81% Upside
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
2.80
Moderate Buy$56.5057.51% Upside
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
0.00
N/AN/AN/A
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NWPHF, ARAV, MNPR, PHAS, and IDYA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$44.00
6/26/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$44.00
6/23/2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$60.00
5/22/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$63.00 ➝ $66.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ARAVIVE, INC stock logo
ARAV
ARAVIVE
$9.14M0.32N/AN/AN/A
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$7M276.38N/AN/A$12.25 per share1.80
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/AN/AN/AN/A$9.02 per shareN/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
$6.82M24.50N/AN/A$0.21 per share44.57
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
$818K0.00N/AN/A($1.93) per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ARAVIVE, INC stock logo
ARAV
ARAVIVE
-$76.32MN/A0.00N/AN/AN/AN/AN/A
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$274.48M-$3.59N/AN/AN/AN/A-29.28%-27.68%8/5/2025 (Estimated)
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$15.59M-$3.48N/AN/AN/AN/A-55.39%-51.53%8/8/2025 (Estimated)
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
-$17.63MN/A0.00N/AN/AN/AN/AN/AN/A
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/A

Latest NWPHF, ARAV, MNPR, PHAS, and IDYA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$0.65-$0.38+$0.27-$0.38N/AN/A
5/6/2025Q1 2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$0.75-$0.82-$0.07-$0.82$2.10 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ARAVIVE, INC stock logo
ARAV
ARAVIVE
N/AN/AN/AN/AN/A
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/AN/AN/AN/AN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/AN/AN/AN/AN/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/AN/AN/AN/AN/A
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ARAVIVE, INC stock logo
ARAV
ARAVIVE
N/AN/AN/A
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/A
13.92
13.92
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/A
36.91
36.91
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/AN/AN/A
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
N/A
0.47
0.47
CompanyEmployeesShares OutstandingFree FloatOptionable
ARAVIVE, INC stock logo
ARAV
ARAVIVE
2073.56 million29.13 millionNo Data
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
8087.58 million85.39 millionOptionable
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
106.12 million4.86 millionNot Optionable
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
2217.85 millionN/ANot Optionable
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
6049.86 million44.92 millionNot Optionable

Recent News About These Companies

MedPharm appoints Bill Humphries as new CEO
Medpharm Appoints Chief Executive Officer
PhaseBio Pharmaceuticals Inc.
PhaseBio Pharmaceuticals, Inc. (PHASQ)
Modified Release Neurology Therapeutics Report 202…
Leading innovators in GLP-1 analogues for the pharmaceutical industry
Alcami Announces CEO Transition
8-K: PhaseBio Pharmaceuticals Inc
BioCryst Appoints Dr. Nancy Hutson as Chair of the Board

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ARAVIVE stock logo

ARAVIVE NASDAQ:ARAV

$0.04 0.00 (0.00%)
As of 07/3/2025

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

IDEAYA Biosciences stock logo

IDEAYA Biosciences NASDAQ:IDYA

$22.09 +0.17 (+0.78%)
As of 07/3/2025 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Monopar Therapeutics stock logo

Monopar Therapeutics NASDAQ:MNPR

$35.87 +0.71 (+2.02%)
Closing price 07/3/2025 01:04 PM Eastern
Extended Trading
$35.87 0.00 (0.00%)
As of 07/3/2025 04:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Newron Pharmaceuticals stock logo

Newron Pharmaceuticals OTCMKTS:NWPHF

$9.36 0.00 (0.00%)
As of 07/3/2025

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.

PhaseBio Pharmaceuticals stock logo

PhaseBio Pharmaceuticals NASDAQ:PHAS

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.